Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Latest Information Update: 21 Apr 2023
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Lung cancer; Meningeal carcinomatosis
- Focus Therapeutic Use
- 21 Apr 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2021).
- 18 Apr 2021 Planned End Date changed from 4 Mar 2023 to 19 Apr 2023.
- 18 Apr 2021 Planned primary completion date changed from 4 Mar 2022 to 19 Apr 2022.